NanoFlash Cell-targeted Biophotonic Nanoparticles for Vision Restoration
- Coordinator
- The Chancellor Masters and Scholars of the University of Cambridge, United Kingdom
- Runs
- 1 May 2026 to 30 April 2030
- Status
- Running
- EU funding
- €3.0m
- Total cost
- €3.0m
- Partners
- 4 organisations in 4 countries
- Type
- European Innovation Council
- Grant agreement
- 101257928
What the project is doing
In the project's own words, from its summary on CORDIS.
NanoFlash aims to develop disruptive nano-enabled technology to restore damaged neuronal networks through precise stimulation of specific retinal cells. Focusing on non-genetic reactivation of physiological vision, NanoFlash targets treatment of retinitis pigments (RP) and age-related macular degeneration (AMD), both marked by severe retinal degradation and loss of high-resolution vision. Current retinal prostheses suffer from low resolution and indiscriminate activation of inner retina, while ontogenetic strategies targeting ON-bipolar cells (BCs) face significant limitation in efficacy and translational readiness.
Circumventing these challenges, NanoFlash will engineer photovoltaic polymer nanoparticles (NPs) functionalist to target mGluR6 receptors, a unigue hallmark on PN-BCs. Using state-of-the-art modelling and bioelectronic in vitro platforms, the project will drive the rational design and optimisation of NPs, tailoring their size, architecture, spectral sensitivity, and transduction efficiency. Advanced organ-on-chip devices will be developed to screen and validate NP targeting and retinal reactivation performance in retinal organdies and explants.
Lead NP candidates will then be tested in rod-cone degeneration rodent models, assessing targeting precision, suspension stability, and visual restoration outcomes. NanoFlash represents a major leap forward in retinal prosthetics by restoring the ON/OFF pathway segregation critical for spatial resolution, contrast sensitivity, and motion detection. This highly interdisciplinary effort will push the frontiers of bio-organic optoelectronics and neurophysiology, providing essential preclinical data toward therapies for currently incurable retinal diseases, addressing a pressing unmet medical need in the EU.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| The Chancellor Masters and Scholars of the University of Cambridge | Cambridge | United Kingdom | Coordinator |
| Universite De Mons | Mons | Belgium | Participant |
| Maxwell Biosystems AG | Zurich | Switzerland | Participant |
| Fondazione Istituto Italiano Di Tecnologia | Genova | Italy | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI